Abigail Beck, APRN
Family · Grayson, KYNPI 1306245360
Payments from drug & device makers
Across 144 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$915
- Lilly USA, LLC$269
- Novo Nordisk$220
- AbbVie$190
- Dexcom, Inc.$121
- Novartis$112
- plus $545 from 16 others
What the payments were for
- Food & beverage$2,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $915 |
| Lilly USA, LLC | 18 | $269 |
| Novo Nordisk | 12 | $220 |
| AbbVie | 9 | $190 |
| Dexcom, Inc. | 7 | $121 |
| Novartis | 7 | $112 |
| Pfizer | 4 | $67 |
| AstraZeneca | 4 | $63 |
| Merck | 4 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Boehringer Ingelheim | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Abbott | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$2,372 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $132,228 |
| JanuviaSitagliptin Phosphate | 132 | $118,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $84,026 |
| OzempicSemaglutide | 54 | $64,741 |
| EliquisApixaban | 56 | $42,088 |
| MounjaroTirzepatide | 28 | $30,019 |
| FarxigaDapagliflozin Propanediol | 18 | $20,320 |
| LinzessLinaclotide | 25 | $19,764 |
| TrulicityDulaglutide | 19 | $18,309 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $18,024 |
| InvokanaCanagliflozin | 23 | $13,161 |
| EntrestoSacubitril/Valsartan | 11 | $11,416 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $8,905 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $8,793 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $7,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $42 | $138,004133 claims |
| MerckJanuvia, Janumet Xr | $57 | $125,517143 claims |
| GSKTrelegy Ellipta | $915 | $84,026116 claims |
| Novo NordiskOzempic | $220 | $64,74154 claims |
| Lilly USA, LLCMounjaro, Trulicity | $269 | $48,32847 claims |
| PfizerEliquis | $67 | $42,08856 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $63 | $38,34437 claims |
| AbbVieLinzess, Synthroid | $190 | $20,93442 claims |
| NovartisEntresto | $112 | $11,41611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Grayson
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.